Robert MD - Jazz Pharmaceuticals Executive Development
| JAZZ Stock | USD 122.64 0.15 0.12% |
Executive
Robert MD is Executive Development of Jazz Pharmaceuticals PLC
| Age | 57 |
| Address | Waterloo Exchange, Dublin, Ireland, D04 E5W7 |
| Phone | 353 1 634 7800 |
| Web | https://www.jazzpharma.com |
Jazz Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0462 % which means that it generated a profit of $0.0462 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1209 %, meaning that it created $0.1209 on every $100 dollars invested by stockholders. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Jazz Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.04 in 2024, whereas Return On Capital Employed is likely to drop 0.06 in 2024. At this time, Jazz Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 8.4 B in 2024, whereas Other Assets are likely to drop slightly above 136.8 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Melissa Manno | Viridian Therapeutics | N/A | |
| Ben Strain | Incyte | N/A | |
| Evett Kruka | Bio Techne Corp | N/A | |
| Tram Bui | Halozyme Therapeutics | N/A | |
| Carole MD | Denali Therapeutics | 51 | |
| Paul MBA | Vaxcyte | 63 | |
| Arjen MSc | argenx NV ADR | 39 | |
| Erik MBA | Ultragenyx | 54 | |
| Gerry Andros | Bio Techne Corp | N/A | |
| Christina Rossi | Blueprint Medicines Corp | 47 | |
| Jeffrey Jensen | Inhibrx | N/A | |
| Jennifer Johansson | Larimar Therapeutics | N/A | |
| Arjun Natesan | Ultragenyx | N/A | |
| Caroline MD | Apellis Pharmaceuticals | 57 | |
| Danielle Keatley | Ultragenyx | N/A | |
| Josep Garcia | Inhibrx | N/A | |
| Shan Wu | Viridian Therapeutics | N/A | |
| Kathryn Haviland | Blueprint Medicines Corp | 48 | |
| Amy Fox | Halozyme Therapeutics | N/A | |
| MD MBA | Halozyme Therapeutics | N/A | |
| David Acheson | Apellis Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0462 |
Jazz Pharmaceuticals PLC Leadership Team
Elected by the shareholders, the Jazz Pharmaceuticals' board of directors comprises two types of representatives: Jazz Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jazz. The board's role is to monitor Jazz Pharmaceuticals' management team and ensure that shareholders' interests are well served. Jazz Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jazz Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Finbar Larkin, VP Operations | ||
| George Eliades, Senior Officer | ||
| Daniel Swisher, NonExecutive Employee | ||
| Patricia Carr, Senior Officer | ||
| Jed MD, Senior Medicine | ||
| Renee Gala, President COO | ||
| Andrea Flynn, VP Relations | ||
| Robert MD, Executive Development | ||
| Philip Johnson, Executive CFO | ||
| Rene Gal, President COO | ||
| John Miller, Senior Strategy | ||
| Heidi Manna, Executive Officer | ||
| Neena JD, Executive Officer | ||
| Samantha Pearce, Senior International | ||
| Bruce Cozadd, Co-Founder, Executive Chairman and CEO |
Jazz Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jazz Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0462 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 11 B | ||||
| Shares Outstanding | 60.45 M | ||||
| Shares Owned By Insiders | 2.93 % | ||||
| Shares Owned By Institutions | 98.79 % | ||||
| Number Of Shares Shorted | 3.82 M | ||||
| Price To Earning | 35.18 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Jazz Stock Analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.